BCAX

$0.00

(

0.00%

) Quote details
Add to Watchlist Run Backtest
stock

Bicara Therapeutics Inc. Common Stock

NASDAQ | BCAX

18.56

USD

(

0.00%

)

At Close (As of Jan 1, 1970)

$1.04B

Market Cap

3.532

P/E Ratio

5.38

EPS

$22.68

52 Week High

$7.80

52 Week Low

HEALTHCARE

Sector

BCAX Chart

Recent Chart
Price Action

BCAX Technicals

Tags:

BCAX Earnings

Yearly Income Statement (As of Dec 31, 2024)

Field Value (USD)
Gross Profit -$56K
Total Revenue $0
Cost Of Revenue $56K
Costof Goods And Services Sold $56K
Operating Income -$82M
Selling General And Administrative $19M
Research And Development $64M
Operating Expenses $82M
Investment Income Net -
Net Interest Income $15M
Interest Income $15M
Interest Expense -
Non Interest Income -
Other Non Operating Income -
Depreciation -
Depreciation And Amortization $56K
Income Before Tax -$68M
Income Tax Expense $187K
Interest And Debt Expense -
Net Income From Continuing Operations -$68M
Comprehensive Income Net Of Tax -
Ebit -$82M
Ebitda -$82M
Net Income -$68M

Revenue & Profitability

Earnings Performance

BCAX Financials

yearly Balance Sheet (As of Dec 31, 2024)

Field Value (USD)
Total Assets $569M
Total Current Assets $503M
Cash And Cash Equivalents At Carrying Value $490M
Cash And Short Term Investments $490M
Inventory -
Current Net Receivables -
Total Non Current Assets $67M
Property Plant Equipment -
Accumulated Depreciation Amortization Ppe -
Intangible Assets -
Intangible Assets Excluding Goodwill -
Goodwill -
Investments -
Long Term Investments -
Short Term Investments -
Other Current Assets $13M
Other Non Current Assets -
Total Liabilities $77M
Total Current Liabilities $18M
Current Accounts Payable $4.5M
Deferred Revenue -
Current Debt -
Short Term Debt $607K
Total Non Current Liabilities $59M
Capital Lease Obligations $738K
Long Term Debt -
Current Long Term Debt -
Long Term Debt Noncurrent -
Short Long Term Debt Total $738K
Other Current Liabilities $13M
Other Non Current Liabilities -
Total Shareholder Equity $492M
Treasury Stock -
Retained Earnings -$221M
Common Stock $7K
Common Stock Shares Outstanding $54M

yearly Cash Flow (As of Dec 31, 2024)

Field Value (USD)
Operating Cashflow -$75M
Payments For Operating Activities -
Proceeds From Operating Activities -
Change In Operating Liabilities -
Change In Operating Assets -
Depreciation Depletion And Amortization $56K
Capital Expenditures $71K
Change In Receivables -
Change In Inventory -
Profit Loss -
Cashflow From Investment -$9K
Cashflow From Financing $334M
Proceeds From Repayments Of Short Term Debt -
Payments For Repurchase Of Common Stock -
Payments For Repurchase Of Equity -
Payments For Repurchase Of Preferred Stock -
Dividend Payout -
Dividend Payout Common Stock -
Dividend Payout Preferred Stock -
Proceeds From Issuance Of Common Stock -
Proceeds From Issuance Of Long Term Debt And Capital Securities Net -
Proceeds From Issuance Of Preferred Stock -
Proceeds From Repurchase Of Equity -
Proceeds From Sale Of Treasury Stock -
Change In Cash And Cash Equivalents -
Change In Exchange Rate -
Net Income -$68M

yearly Income Statement (As of Dec 31, 2024)

Field Value (USD)
Gross Profit -$56K
Total Revenue $0
Cost Of Revenue $56K
Costof Goods And Services Sold $56K
Operating Income -$82M
Selling General And Administrative $19M
Research And Development $64M
Operating Expenses $82M
Investment Income Net -
Net Interest Income $15M
Interest Income $15M
Interest Expense -
Non Interest Income -
Other Non Operating Income -
Depreciation -
Depreciation And Amortization $56K
Income Before Tax -$68M
Income Tax Expense $187K
Interest And Debt Expense -
Net Income From Continuing Operations -$68M
Comprehensive Income Net Of Tax -
Ebit -$82M
Ebitda -$82M
Net Income -$68M

BCAX Profile

Bicara Therapeutics Inc. Common Stock Profile

Sector: HEALTHCARE

Industry: BIOTECHNOLOGY

Bicara Therapeutics Inc. (BCAX) is an innovative clinical-stage biopharmaceutical firm headquartered in Boston, focused on advancing bifunctional therapeutics for the treatment of solid tumors. Utilizing a distinctive dual-targeting strategy, the company aims to enhance antitumor effectiveness while minimizing systemic toxicity, thereby redefining cancer treatment paradigms. With a robust pipeline of promising lead candidates in clinical trials, Bicara is strategically positioned to make meaningful advancements in oncology and establish a significant presence in the evolving landscape of cancer therapeutics.

LPTX
+368.57%
$2.05
VHAI
0.00%
$0.00
KTTA
+38.67%
$1.47
VINE
+10.76%
$0.39
NVDA
-1.80%
$177.00
ONDS
-2.36%
$8.24
HBI
-1.82%
$6.47
AMZE
+19.82%
$0.47
TLRY
-21.06%
$0.81
INTC
+10.18%
$40.56
BITF
+12.25%
$3.48
IPG
-1.95%
$24.57
YGMZ
-9.59%
$0.11
AXDX
-61.36%
$0.03
BYND
-3.74%
$0.98
BMNR
+4.53%
$33.18
CLSK
+12.26%
$15.10
ADAP
-15.14%
$0.05
RUBI
-26.17%
$0.15
ASST
-0.88%
$1.12
PLUG
+1.51%
$2.01
SOND
-23.45%
$0.12
RMBL
+60.50%
$3.21
LNW
-3.71%
$86.22
ADD
-25.47%
$0.05
AAL
+0.86%
$14.05
BIYA
+17.05%
$0.29
SNAP
+0.72%
$7.66
INHD
-0.97%
$0.22
TSLA
+0.84%
$430.17
SRM
+53.27%
$10.30
CHR
-3.48%
$0.04
CIFR
+6.26%
$20.35
ONMD
+30.28%
$1.85
BMNU
+8.77%
$8.18
MARA
+6.30%
$11.81
WULF
+4.51%
$15.51
NIO
+0.82%
$5.50
BULL
+6.43%
$9.26
F
+0.45%
$13.25
TWOH
0.00%
$0.00
WLGS
-5.57%
$0.04
MTSR
-0.35%
$70.50
BURU
+10.43%
$0.24
GPUS
-8.58%
$0.30
VALE
+0.79%
$12.61
SOFI
+4.31%
$29.72
GOOGL
+0.07%
$320.18
BTBT
+2.58%
$2.38
DVLT
-3.61%
$2.13
DEFT
+9.35%
$1.52
ADTX
+21.01%
$3.80
BTG
+3.80%
$4.64
AFMD
-34.94%
$0.18
ACHR
+4.40%
$7.82
GRAB
+2.44%
$5.45
CAN
+0.75%
$0.92
HPQ
-1.39%
$23.98
CRCL
+10.02%
$79.92
KWM
+13.63%
$0.75
SMX
+250.80%
$61.04
DNN
-0.19%
$2.55
IBRX
+10.79%
$2.36
RIOT
+7.82%
$16.13
PFE
0.00%
$25.71
AMZN
+1.77%
$233.22
AAPL
+0.46%
$278.85
WBD
+0.50%
$24.00
AIIO
-9.09%
$0.70
APLD
+8.66%
$27.10
GOOG
-0.05%
$320.12
NGD
+6.76%
$8.37
VEEE
+45.50%
$2.59
IREN
-1.32%
$47.81
RIG
+2.09%
$4.39
GRYP
-10.38%
$1.38
AG
+8.86%
$13.51
BAC
+1.28%
$53.67
MODV
-25.22%
$0.43
AMD
+1.53%
$217.53
AMCR
+1.29%
$8.62
RR
-3.35%
$3.46
RIVN
+4.20%
$16.86
SMR
+5.04%
$20.00
TMC
+19.38%
$6.96
CDE
+6.76%
$17.28
PLTR
+1.61%
$168.45
ITUB
+1.82%
$7.80
AGNC
-0.66%
$10.49
KDLY
+7.20%
$0.49
CRCA
+19.56%
$4.40
T
+0.69%
$26.00
AMC
+6.30%
$2.44
NVO
+1.21%
$49.30
CRCG
+20.00%
$2.82
MSTR
+0.87%
$177.18
NFLX
+1.35%
$107.58
SAND
-6.04%
$12.12
BBD
+0.67%
$3.70
HBAN
+0.18%
$16.30
LPTX
+368.57%
$2.05
VHAI
0.00%
$0.00
KTTA
+38.67%
$1.47
VINE
+10.76%
$0.39
NVDA
-1.80%
$177.00
ONDS
-2.36%
$8.24
HBI
-1.82%
$6.47
AMZE
+19.82%
$0.47
TLRY
-21.06%
$0.81
INTC
+10.18%
$40.56
BITF
+12.25%
$3.48
IPG
-1.95%
$24.57
YGMZ
-9.59%
$0.11
AXDX
-61.36%
$0.03
BYND
-3.74%
$0.98
BMNR
+4.53%
$33.18
CLSK
+12.26%
$15.10
ADAP
-15.14%
$0.05
RUBI
-26.17%
$0.15
ASST
-0.88%
$1.12
PLUG
+1.51%
$2.01
SOND
-23.45%
$0.12
RMBL
+60.50%
$3.21
LNW
-3.71%
$86.22
ADD
-25.47%
$0.05
AAL
+0.86%
$14.05
BIYA
+17.05%
$0.29
SNAP
+0.72%
$7.66
INHD
-0.97%
$0.22
TSLA
+0.84%
$430.17
SRM
+53.27%
$10.30
CHR
-3.48%
$0.04
CIFR
+6.26%
$20.35
ONMD
+30.28%
$1.85
BMNU
+8.77%
$8.18
MARA
+6.30%
$11.81
WULF
+4.51%
$15.51
NIO
+0.82%
$5.50
BULL
+6.43%
$9.26
F
+0.45%
$13.25
TWOH
0.00%
$0.00
WLGS
-5.57%
$0.04
MTSR
-0.35%
$70.50
BURU
+10.43%
$0.24
GPUS
-8.58%
$0.30
VALE
+0.79%
$12.61
SOFI
+4.31%
$29.72
GOOGL
+0.07%
$320.18
BTBT
+2.58%
$2.38
DVLT
-3.61%
$2.13
DEFT
+9.35%
$1.52
ADTX
+21.01%
$3.80
BTG
+3.80%
$4.64
AFMD
-34.94%
$0.18
ACHR
+4.40%
$7.82
GRAB
+2.44%
$5.45
CAN
+0.75%
$0.92
HPQ
-1.39%
$23.98
CRCL
+10.02%
$79.92
KWM
+13.63%
$0.75
SMX
+250.80%
$61.04
DNN
-0.19%
$2.55
IBRX
+10.79%
$2.36
RIOT
+7.82%
$16.13
PFE
0.00%
$25.71
AMZN
+1.77%
$233.22
AAPL
+0.46%
$278.85
WBD
+0.50%
$24.00
AIIO
-9.09%
$0.70
APLD
+8.66%
$27.10
GOOG
-0.05%
$320.12
NGD
+6.76%
$8.37
VEEE
+45.50%
$2.59
IREN
-1.32%
$47.81
RIG
+2.09%
$4.39
GRYP
-10.38%
$1.38
AG
+8.86%
$13.51
BAC
+1.28%
$53.67
MODV
-25.22%
$0.43
AMD
+1.53%
$217.53
AMCR
+1.29%
$8.62
RR
-3.35%
$3.46
RIVN
+4.20%
$16.86
SMR
+5.04%
$20.00
TMC
+19.38%
$6.96
CDE
+6.76%
$17.28
PLTR
+1.61%
$168.45
ITUB
+1.82%
$7.80
AGNC
-0.66%
$10.49
KDLY
+7.20%
$0.49
CRCA
+19.56%
$4.40
T
+0.69%
$26.00
AMC
+6.30%
$2.44
NVO
+1.21%
$49.30
CRCG
+20.00%
$2.82
MSTR
+0.87%
$177.18
NFLX
+1.35%
$107.58
SAND
-6.04%
$12.12
BBD
+0.67%
$3.70
HBAN
+0.18%
$16.30
2025 © AfterPullback LTD

Charts powered by TradingView

Market data may be delayed by 15 minutes or more and is provided by financial exchanges or third-party providers. AfterPullback does not verify or guarantee its accuracy and assumes no responsibility to do so. This website is not operated by a licensed attorney, accountant, or financial advisor. Nothing on this site constitutes financial advice or replaces consultation with a qualified professional who understands your specific circumstances. Always consult a licensed financial advisor before making investment decisions.